LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

Home・Listă Acțiuni・Puma Biotechnology Inc

Puma Biotechnology Inc

Deschisă

SectorSănătate

7.18 1.84

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

7.04

Maxim

7.22

Indicatori cheie
By Trading Economics
Venit	-16M -3.8M
Vânzări	-31M 45M
P/E Medie Sector	14.875 51.415
EPS	-0.04
Marjă de profit	-8.377
Angajați	179
EBITDA	-28M -1.3M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-29.38% downside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-20M 363M
Deschiderea anterioară	5.34
Închiderea anterioară	7.18

Sentimentul știrilor

By Acuity

50%

162 / 346 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

3.07 / 3.075 Suport & Rezistență

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 mai 2026, 22:54 UTC

Câștiguri

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13 mai 2026, 23:17 UTC

Câștiguri

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mai 2026, 23:16 UTC

Câștiguri

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mai 2026, 23:15 UTC

Câștiguri

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mai 2026, 23:14 UTC

Câștiguri

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mai 2026, 23:02 UTC

Market Talk

Câștiguri

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mai 2026, 22:59 UTC

Market Talk

Câștiguri

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mai 2026, 22:24 UTC

Câștiguri

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mai 2026, 22:23 UTC

Câștiguri

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mai 2026, 22:23 UTC

Câștiguri

Xero FY International Revenue Growth 47%>XRO.AU

13 mai 2026, 22:22 UTC

Câștiguri

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mai 2026, 22:19 UTC

Câștiguri

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mai 2026, 22:19 UTC

Câștiguri

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mai 2026, 22:18 UTC

Câștiguri

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mai 2026, 22:16 UTC

Câștiguri

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mai 2026, 22:15 UTC

Câștiguri

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mai 2026, 22:15 UTC

Câștiguri

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mai 2026, 22:13 UTC

Câștiguri

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mai 2026, 22:12 UTC

Câștiguri

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mai 2026, 22:11 UTC

Câștiguri

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mai 2026, 22:11 UTC

Câștiguri

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mai 2026, 22:10 UTC

Câștiguri

Xero Did Not Declare a Dividend>XRO.AU

13 mai 2026, 22:10 UTC

Câștiguri

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mai 2026, 22:09 UTC

Câștiguri

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mai 2026, 22:00 UTC

Câștiguri

Cisco to Shed Jobs for All-In AI Push -- Update

13 mai 2026, 21:11 UTC

Câștiguri

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

-29.38% jos

Prognoză pe 12 luni

Medie 5 USD -29.38%

Maxim 5 USD

Minim 5 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Puma Biotechnology Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

3.07 / 3.075Suport & Rezistență

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

162 / 346 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.